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Pancreatitis is a global health care problem with variedaetiologies. Alcoholism is responsible in the majority ofpatients while other causes, such as heredity, gallstones,
hyperlipidaemia, hypercalcaemia, and idiopathic pancreatitis,
are relatively rare.1 2 The causal factor in 20-30% of such cases
is still not known and they fall into the category of idiopathic
chronic pancreatitis (ICP).1 2 Although the exact pathogenesis
is not clear, autodigestion secondary to aberrant intraductal
activation of zymogens by trypsin is a primary common event.
A genetic basis was reported in 1996 by familial linkage
analysis3–5 and confirmed by detection of missense mutations,
namely R122H and N29I, in the cationic trypsinogen gene
(PRSS1) in hereditary pancreatitis (HP) patients.6 7 HP is a
relatively rare autosomal dominant disorder where typical
acute attacks in childhood and frequent progression to
chronic pancreatitis are seen to occur in two or more subjects
or generations. Subsequent studies from other parts of the
world have also reported the two common mutations8 9 and
other mutations in the PRSS1 gene in both HP and ICP
patients.8 10 11 However, only about 60% cases of HP and less
than 20% with a diagnosis of ICP have a mutated PRSS1 gene,
suggesting the presence of other candidate genes.
Pancreatic secretory trypsin inhibitor (PSTI/SPINK1) is a
potent protease inhibitor and thought to be a major protective
mechanism preventing inappropriate activation of pancreatic
digestive enzyme cascade by inhibiting up to 20% of potential
trypsin activity.12 The human SPINK1 gene on chromosome 5 is
approximately 7.5 kb long with four exons and codes for a
product of 79 amino acids including a signal peptide of 23
amino acids.13 Since the inhibitor molecule provides the first
line of defence against prematurely activated trypsinogen
within the pancreas, it has recently attracted attention as a
possible cause of chronic pancreatitis. A causal role for the
SPINK1 gene was ruled out initially,14 but a significant correla-
tion between mutated SPINK1 and chronic pancreatitis was
first shown byWitt et al15 and subsequently supported by Pfut-
zer et al.16 A founder mutation N34S was detected in the
majority of patients, while another variant P55S was
identified in only a few. In contrast, two recent analyses have
reported a very low prevalence of SPINK1 gene mutations. Five
(three with N34S) out of 32 Japanese patients17 and only two
(one with N34S) out of 20 German adult patients with
idiopathic chronic pancreatitis18 had a mutated SPINK1 gene.
Tropical calcific pancreatitis (TCP) is an idiopathic, juvenile,
non-alcoholic form of chronic pancreatitis widely prevalent in
several tropical countries, and fibrocalculous pancreatic
diabetes (FCPD) is a form of diabetes secondary to TCP.19 The
disease differs from alcoholic pancreatitis by a much younger
age of onset, pancreatic calcification, a high incidence of insu-
lin dependent but ketosis resistant diabetes mellitus, and an
exceptionally high incidence of pancreatic cancer. Although
two studies have reported a lack of common mutations in
PRSS1 in FCPD patients, neither of them analysed the whole
PRSS1 gene.20 21 The genetic basis of TCP without diabetes has
also not been fully investigated. A recent study based on
analysis of eight FCPD and four TCP patients (without
diabetes) has shown that SPINK1 mutations are associated
with FCPD but not with TCP.22 We have analysed 68 clinically
and radiologically confirmed TCP patients (24 FCPD and 44
TCP patients without diabetes mellitus) for mutations in the
cationic trypsinogen and pancreatic secretory trypsin inhibi-
tor genes in an attempt to understand their respective roles in
the pathogenesis of tropical calcific pancreatitis in our
population.
SUBJECTS AND METHODS
Patients
Seventy unrelated patients comprising 47 males and 23
females were diagnosed as having tropical calcific pancreatitis
based on the following WHO criteria23: (1) recurrent pain in
the abdomen since childhood; (2) large intraductal calculi,
particularly in the head region; (3) ultrasonological and ERCP
evidence of pancreatic calcification; (4) absence of any other
aetiological factor like alcoholism, etc; (5) diabetes mellitus as
defined by the WHO Study group E (may or may not be
present).
DNA analysis
After obtaining informed consent, EDTA blood samples were
collected from 68 patients (one male and one female patient
refused to participate in the study) and 100 healthy volunteers
who served as controls. Genomic DNA was isolated from per-
ipheral blood leucocytes following standard protocols. In view
of the extremely high homology of the PRSS1 gene with that of
the other pseudogenes, all five exons of PRSS1 were amplified
using a nested PCR strategy.9 The primer sequences for the
analysis of the promoter region and the four exons of the
SPINK1 gene were selected from published sequences.15 The
PCR conditions were optimised in a way that the amount of
unused primers or unincorporated dNTPs was minimal in the
post-PCR reaction mix. All the exons were sequenced
individually on both the strands using internal sequencing
primers and Big dye terminator cycle sequencing ready kit and
an ABI 310 Genetic Analyzer (Applied Biosystems).
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Statistical analysis
All values are presented as median (range, 95% CI) and statis-
tical analysis was performed applying the Mann-Whitney U
test using SPSSR for Windows software (SPSS Inc, Chicago,
IL).
RESULTS
Sequence analysis of the PRSS1 gene
We have analysed all the exons and intron-exon boundaries of
the cationic trypsinogen gene in 68 well characterised TCP
patients. Sequence analysis of the PRSS1 gene on both strands
showed none of the reported mutations like R122H, N29I,
A16V, K23R, or D22G nor any novel variant in these patients.
This is in contrast to earlier studies, which reported a mutated
PRSS1 gene in patients with HP and ICP.6 8 9 Two earlier studies
have reported a lack of common mutations (exons 2 and 3
only) in PRSS1 in patients with FCPD and TCP.However, one of
them performed a PCR-RFLP assay for the R122Hmutation on
11 FCPD and five TCP patients only20 and the other one
analysed FCPD patients only.21 In agreement with earlier
reports, single C to T transitions in exon 4 (162Asp
(GAC-GAT)) and exon 5 (246Asn (AAC-AAT)) without amino
acid substitution were identified in the majority of patients
(85%) as well as in normal controls (90%).7–9
Sequence analysis of the SPINK1 gene
Direct sequencing of the coding exonic and flanking intronic
sequences including the promoter region of SPINK1 detected
mutations in 32 out of 68 patients analysed. Of 31 patients
with N34S mutation, eight were homozygous (N34S/N34S),
22 heterozygous (N34S/wt), and one compound heterozygous
with P55S (N34S/P55S) (fig 1). Only one other patient had a
heterozygous P55S mutation (table 1). We have detected
SPINK1 mutations in both FCPD patients and TCP patients
without diabetes mellitus. This is at variance with a recent
study that reported mutated SPINK1 in six out of eight FCPD
patients, but none in four TCP patients from Bangladesh.22 We
also report the highest frequency of 46% for the N34S muta-
tion reported so far in comparison to 41% (five out of 12
patients) by Rossi et al22 and 26% by Pfutzer et al.16 A novel G to
T transversion at 215 bp upstream in the SPINK1 promoter
region (−215G>T) was also identified in three patients (fig 2).
Interestingly, all three patients also carried an N34S allele,
suggesting a compound heterozygote status. Sequencing of
200 control alleles detected three N34S heterozygous muta-
tions (1.5%), one P55S heterozygous mutation (0.5%), but
none with the −215G>T mutation. The IVS1-37T>C polymor-
phism was found to be in complete linkage disequilibrium
with the N34S mutation. Another previously reported SNP,
−253T>C,was detected in six patients and one of them carried
N34S on the other allele. The frequency of this mutation in
control chromosomes was 22% with one homozygote and
another compound heterozygote with the N34S mutation.
This only substantiates the already established notion that
−253T>C is a neutral polymorphism.14 No additional muta-
tions were detected in these patients.
Table 1 Distribution of mutations and polymorphisms in the PSTI gene in patients
with tropical calcific pancreatitis and controls
Location Polymorphism Patients (n=68) Controls (n=100)
5′ UTR −253T>C* 6 (6 het) (0.04) 43 (42 het) (0.22)
−215G>A 0 0
−215G>T† 3 (3 het) (0.02) 0
−53C>T 0 0
−41G>A 0 0
−22C>T 0 0
Exon 1 2T>C (M1T) 0 0
41T>C (L14P) 0 0
Intron 1 IVS1-37T>C‡ 31 (8 hom) (0.29) 3 (3 het) (0.015)
Exon 3 101A>G (N34S) 31 (8 hom) (0.29) 3 (3 het) (0.015)
150T>G (D50E) 0 0
163C>T (P55S) 02 (2 het) (0.015) 1 (1 het) (0.005)
174C>T (C58C) 0 0
194G>A (R65Q) 0 0
Intron 3 IVS3+2T>C 0 0
IVS3+125C>A 0 0
IVS3+184T>A 0 0
Exon 4 231G>A (G77G) 0 0
3′-UTR 272C>T 0 0
hom=homozygous; het=heterozygous. Allelic status and frequencies are given in parentheses.
*The −253T>C variation was found in a normal subject heterozygous for the N34S mutation.
†Novel mutation, not previously reported.
‡Detected on all alleles with N34S.
Figure 1 DNA sequencing electropherogram of exon 3 of the
human SPINK1 gene showing an A to G transition in a patient with
tropical calcific pancreatitis. This mutation leads to an amino acid
substitution from Asn to Ser (N34S). The arrowhead indicates the
altered nucleotide. (A) Homozygous state. (B) Heterozygous state.
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Clinical phenotype
The median age of onset and age of presentation for FCPD
patients was 35.0 years (95% CI 27.6-40.2) and 44.0 (95% CI
39.3-49.3), which is significantly higher than that of TCP
patients without diabetes mellitus (21.0 years (95% CI
19.9-27.1), p<0.004) and (26.0 (95% CI 25.7-33.0), p<0.001),
respectively (table 2). A comparison of SPINK1 mutation
frequency in FCPD patients and TCP patients without diabetes
showed similar trends, suggesting that neither these muta-
tions nor their status is directly related to the presentation of
diabetes mellitus (table 2). No significant difference could be
noted on comparison of parameters like the age of onset, pres-
ence or absence of diabetes mellitus, and age of onset of
diabetes between SPINK1 N34S heterozygous, homozygous, or
compound heterozygous patients (data not shown).
DISCUSSION
Tropical calcific pancreatitis is a variant of chronic pancreatitis
of unknown aetiology, occurring mostly in developing
countries in tropical regions, and fibrocalculous pancreatic
diabetes is a form of diabetes secondary to TCP.24 The aetiology
of FCPD is suggested to be multifactorial with both
environmental and genetic components.19 25 It has also been
suggested that FCPD occurs in a person with susceptibility to
diabetes mellitus and might be a distinct entity. The exact
relationship between the phenotype of FCPD and TCP is still
not clear, although there is an overlap. In our study cohort of
68 TCP patients, 24 were FCPD patients while the remaining
44 were without diabetes at the time of presentation.
Comparison of the age of onset shows that FCPD patients had
a late age of onset with a difference of more than a decade (21
years v 35 years). It has also been shown that patients with
TCP are younger than the FCPD patients and the majority of
them have an abnormal glucose tolerance test (GTT).26 This
strongly suggests that FCPD may be gradually evolving
diabetes in the background of tropical calcific pancreatitis.
In the present study, no mutation could be seen in the cati-
onic trypsinogen gene except two neutral polymorphisms
(D162D and N246N) reported earlier.7 9 A pilot study from
Bangladesh on 11 FCPD and five chronic calcific pancreatitis
patients without diabetes mellitus reported lack of R117H
mutation in the PRSS1 gene.20 Subsequent extension of the
study to include 50 South Indian and 70 Bangladeshi patients
with FCPD excluded common mutations in exons 2 and 3 of
the PRSS1 gene.21 Ours is the first report where analysis of the
whole coding sequence of the cationic trypsinogen gene does
not show any causal mutation in TCP patients. Trypsin plays a
central role in pancreatic exocrine physiology by acting as a
trigger enzyme leading to activation of all other pancreatic
zymogens. A number of protective mechanisms are involved in
combating prematurely activated trypsinogen. The current
model of PRSS1 mutations suggests that the identified muta-
tions cause enhanced autoactivation of trypsinogen to trypsin
or prevent prematurely activated trypsin from being inacti-
vated by autolysis.16 Earlier reports on the presence of identi-
cal mutations in Mongolians and the white HP kindreds sug-
gest heterogeneity but no racial specificity.9 Hence, it is
surprising that no mutation could be detected in the PRSS1
gene in these patients. Our results show that the established
mutations in the cationic trypsinogen gene are not a common
cause of tropical calcific pancreatitis in the Indian population.
This study also confirms the causal role of the N34S muta-
tion in the SPINK1 gene in pancreatitis and simultaneously
establishes the role of mutated inhibitor in the pathogenesis of
tropical calcific pancreatitis. Analysis of the phenotype in
terms of the age of onset, frequency of attacks, and presence
and age of onset of diabetes mellitus did not show any signifi-
cant difference between N34S heterozygous or homozygous
patients. In addition to the previously reported mutations, we
have identified a novel −215G>T mutation which was not
found in any of the controls. These three patients were
compound heterozygotes with the N34S mutation and had
late onset disease with diabetes mellitus, consistent with the
FCPD phenotype. This mutation has never been reported pre-
viously, although a recent study reported −215G>A in the
homozygous state in two out of 32 patients.17 Since SPINK1
N34S heterozygous and homozygous patients have a similar
phenotype, it is presumed that mutated SPINK1 cannot cause
disease independently by autosomal dominant or recessive
mechanisms and the presence of a second mutation, either in
Figure 2 DNA sequencing electropherogram of the promoter
region of the human SPINK1 gene showing a heterozygous G to T
change at nt 215 upstream from the translation initiation site
(−215G>T) in a patient with tropical calcific pancreatitis. The
mutation was absent in 200 alleles from normal subjects. The
arrowhead indicates the altered nucleotide.
Table 2 Clinical data and status of SPINK1 mutations in the study population
TCP with diabetes (FCPD) TCP without diabetes Total
Number 24 (17 M/7 F) 44 (29 M/15 F) 68 (46 M/22 F)
Age at onset (median, range, 95% CI) 35.0 y (27.6-40.2) 21.0 y (19.9-27.1) 24.0 y (23.8-30.5)
Age at presentation (median, range, 95% CI) 44.0 y (39.3-49.3) 26.0 y (25.7-33.0) 33.5 y (31.3-38.0)
SPINK1 mutation 12 20 32
Homozygous 4 4 8
Heterozygous 8 16 24
N34S/WT 6 16 22
N34S/P55S* 1 – 1
P55S/WT 1 – 1
WT=wild type.
*One patient was found to be a compound heterozygote for N34S and P55S mutations.
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the same gene or other genes, is required to express the
disease phenotype.16 It may be hypothesised that the mutation
−215G>T lies in an unknown cis acting element and may
affect transcription of mutated SPINK1 with an already
compromised functional capability.17 It may be interesting to
dissect the role of this mutation on SPINK1 expression and its
interaction with the N34S mutation.
Based on the detection of mutated SPINK1 in FCPD patients
only, Rossi et al22 have suggested a genetic basis for FCPD only
and also made it the criterion for clinical distinction within
TCP with respect to the presence or absence of diabetes melli-
tus. However, their limited sample size (eight FCPD and four
TCP patients) raises serious concern about the validity of such
a conclusion. We have detected SPINK1 mutations in both
FCPD patients and TCP patients without diabetes (table 2).
Our results suggest a common genetic basis for tropical calcific
pancreatitis and there could be additional genetic/
environmental factors responsible for the variability of
phenotype in TCP and FCPD.
Such a high frequency of SPINK1 gene mutations on the
background of complete absence of a mutated PRSS1 gene is
interesting. To date, no study has reported concurrence of
mutated PRSS1 with SPINK1, suggesting that both the
mutations work through different and independent mecha-
nisms. However, this pancreatic protease-protease inhibitor
system is very important, considering the physiological inter-
action between them in combatting the prematurely activated
trypsinogen inside the pancreas. Intrapancreatic levels of
trypsin are expected to be raised if mutations in the inhibitor
molecule lead to loss of its inhibitory capacity. However, it is
difficult to explain the phenotype of pancreatitis in the
presence of normal trypsin when the intact R122 autolysis
“self-destruct” mechanism can take care of the prematurely
activated trypsin molecule. This suggests impairment of other
protectivemechanisms involved in combating the prematurely
activated trypsin molecule inside the pancreas. The exact
mechanism is still not clear and it remains to be proven how
the prematurely activated trypsin is sustained inside the pan-
creatic acini and may cause a low grade inflammation and
disease. SPINK1mutations have been proposed significantly to
lower the threshold for pancreatitis from other factors; we
suggest the involvement of other genetic/environmental
factors in FCPD and TCP patients without diabetes. Several
studies have reported mutations in the cystic fibrosis
transmembrane regulator (CFTR) gene in both HP and
sporadic pancreatitis.27 28 Based on the finding that the vast
majority of these patients are heterozygous for the mutation,
CFTR has been suggested to act as a modifier gene in the
pathogenesis of pancreatitis. A recent study has indicated an
association between CFTR mutations and TCP patients;
however, only 18 TCP patients have been analysed with two
females showing mutations.29 Screening a larger cohort of TCP
patients may provide more information about the modifier
mutations in the CFTR gene.
In conclusion, our study strongly suggests that cationic
trypsinogen gene mutations may not have a role in TCP in our
population. We have also shown for the first time the
association of mutated inhibitor with tropical calcific pancrea-
titis, irrespective of the absence or presence of diabetes melli-
tus (FCPD). The presence of SPINK1 mutations in both FCPD
and TCP patients without diabetes mellitus suggests a
common genetic basis for tropical calcific pancreatitis.
However, different genetic/environmental factors may be
involved to account for phenotypic variability in TCP patients.
In view of the absence of cationic trypsinogen mutations but
significant association of SPINK1 mutations, it may be
hypothesised that TCP may occur as a result of mutation in
SPINK1 or as a result of a combination of genetic defects of
SPINK1 and as yet unidentified genes or environmental
factors. As was true for HP acting as a model for understand-
ing the pathophysiology of other types of pancreatitis, the
findings from this study will be critical in understanding the
variability in the genetic background and association with the
variability of phenotype in FCPD and TCP. Considering the fact
that about 50% of TCP patients have a mutated SPINK1 gene
with the majority having N34S mutation as a founder
mutation, patients with pancreatitis may be screened and
informed about the risk of developing the disease. An appro-
priate prevention strategy could be suggested to help the car-
riers of the mutated allele in modifying the late stage compli-
cations of TCP.
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